Sign In

Andrey Doronichev

CEO at Optic, AI Drug Discovery.

Andrey Doronichev is a versatile professional with a rich background in tech and entrepreneurship. He currently serves as the Founder and CEO of Optic, where he focuses on developing an AI engine for drug discovery. Prior to this role, Andrey held key positions at major tech companies including YouTube and Google, where he notably served as the Head of Mobile at YouTube and as the Director of Product at Stadia and Google AR/VR. He is also known for his presence on Instagram as @dobry.

In terms of education, Andrey pursued Executive Business Education at the University of California, Berkeley, Haas School of Business. He also holds a Master of Science in Computer Science from the Higher School of Economics and a degree in AVT from the Moscow Institute of Electronics and Mathematics (Technical University).

Throughout his career, Andrey has been associated with several notable organizations, having served in leadership roles such as Founder, CEO at Optic, Co-Founder at Mesto, Director of Product Management at Google, Head of Mobile at YouTube, and more. His diverse experience encompasses product management, co-founding ventures, and technical program management in reputable companies like Google and Golden Telecom.

Andrey Doronichev's expertise spans across technology, entrepreneurship, product management, AI, drug discovery, mobile applications, and virtual reality. With a strong educational foundation and a history of holding key leadership positions in renowned organizations, Andrey continues to make significant contributions to the tech industry.

Highlights

Jul 15 · linkedin

There are two types of AIs in the world: "magic" and "boring."

"Magic" AI tools tackle problems beyond human capacity, like predicting protein structures (AlphaFold) or screening billions of molecules swiftly (BIOPTIC). On the other hand, "boring" AIs sometimes show even more impact by automating mundane tasks and eliminating tedious work like emailing CROs to request quotes for synthesizing molecules.

At OPTIC, we combine the best of both worlds. While at the core of our BIOPTIC platform is a proprietary model for "magic" small molecule discovery, in our latest release we've added some new "boring" LLM-based workflow automation tools. Our aim? To help biotech R&D teams move faster with AI, whether through extraordinary feats or everyday automation.

What's new ◾ BIOPTIC Copilot: An LLM-based agent that automates routine workflows like literature research and can select and use various tools (both internal and external) for drug discovery. Try it for something like “let’s find a drug for Parkinson's.” ◾ BIOPTIC Flows: A workflow automation tool that lets us create pipelines, refine them interactively, and integrate seamlessly into workflows, enhancing productivity and collaboration. ◾ Tanimoto Similarity Search: A textbook similarity search tool that enables exploration of vast chemical spaces by structural similarity.

Curious to explore? Visit app.bioptic.io and share your thoughts!

There are two types of AIs in the world: "magic" and "boring." 

"Magic" AI tools tackle problems be
May 4 · linkedin

I'm a computer scientist who now works in biotech and writes poetic blogposts in Russian. How come? What do AI, poetry, and biology have in common? Language.

At school I hated Russian grammar class. Learning a language by its rules is like learning to dance from a book. Even if you master a thousand rules and a million exceptions, it doesn't guarantee you'll write well.

A natural language isn't designed; it's evolved. It wasn't developed, it developed. Studying grammar helps, but the only real way to master a language is through developing intuition – by reading, writing, and speaking a lot.

Turns our the same applies to computers. For years, we tried to teach them natural language through complex logic, grammar rules, and it went even worse than my Russian lessons. Remember those dumb chatbots from a decade ago?

But then, large language models (AI) arrived, and instead of programming on linguistic rules, we just had them "read" a lot, basically every text in existence. And now, ChatGPT writes in almost every natural language better than humans.

But the most exciting part lies ahead. See, biology is also a language in a way — the Language of Life. Amino acids are the "letters," proteins the "words," biochemical pathways the "sentences," and every cell is an "epic" of 94 million words.

This language, too, is the product of evolution, yet far more complex than Russian. For centuries, we've tried unsuccessfully to decode it by rules, and we've only managed to create something akin to the first chatbots. But soon, AI will change everything.

At OPTIC we're building a translator at the crossroads of AI and biology. I believe that once we find an optimal, scalable way to collect daya and let machines read all the existing "texts in the language of life," we'll develop a model capable of writing in it.

Can you imagine the possibilities when the "ChatGPT moment" happens in biology? A cure for every disease? Personalized therapy for everyone? An end to aging?

— "Ok, BIOPTIC, cure Parkinson's disease." — "HDEKKPKNFFGWKDHEQCMHPKSIM…🫶"

This is what drives me to work every morning.

Andrey Doronichev
Add to my network

Location

San Francisco, California, United States